Trial Profile
A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Safety and Efficacy (AMBER)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2021
Price :
$35
*
At a glance
- Drugs Patiromer (Primary) ; Spironolactone
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors Relypsa
- 14 Apr 2021 Results assessing the prespecified subgroups by sex, biological differences between men and women contribute to variations in drug response, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
- 03 Mar 2021 According to a Vifor media release, European Medicines Agency approved important changes to the label in December which included data from the phase-II AMBER clinical study.
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes